Imatinib Amarox

Imatinib, the active ingredient in Imatinib Amarox, is a tyrosine kinase inhibitor presented as a oral tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib Amarox belongs to the tyrosine kinase inhibitor class and is indicated for several malignancies driven by BCR‑ABL, c‑KIT or PDGFR signaling. - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission by targeting the BCR‑ABL fusion protein. - Gastrointestinal stromal tumor (GIST): blocks c‑KIT driven tumor growth, leading to disease control.

Adverse reactions may occur with any tyrosine kinase inhibitor therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Fatigue: generalized tiredness. - Diarrhea: loose stools, usually self‑limited. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Cardiotoxicity: decreased left ventricular ejection fraction. - Severe neutropenia: marked reduction in white blood cells. - Hemorrhage: bleeding complications, especially with concomitant anticoagulants.

Before initiating therapy, clinicians should assess baseline organ function and monitor throughout treatment. - Baseline labs: obtain complete blood count, liver and renal function tests. - Cardiac assessment: evaluate ejection fraction in patients with cardiac history. - Drug interactions: review concomitant medications for CYP3A4 substrates or inhibitors. - Pregnancy and lactation: avoid use unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Imatinib may alter the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib exposure and toxicity. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering drug levels.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors): can modestly decrease absorption. - Anticoagulants (e.g., warfarin): may enhance bleeding risk. - Vaccines: live attenuated vaccines should be avoided during therapy.